A Novel and Simple Method for Rapid Generation of Recombinant Porcine Adenoviral Vectors for Transgene Expression

Peng Zhang, Enqi Du, Jing Ma, Wenbin Wang, Lu Zhang, Suresh K. Tikoo, Zengqi Yang

1 College of Veterinary Medicine, North-west A&F University, Yangling, Shaanxi, China, 2 VIDO-InterVac, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 3 Vaccinology & Immunotherapeutics Program, School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 4 Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

☯ These authors contributed equally to this work.
* zyq8162@163.com (ZY); suresh.tik@usask.ca (SKT)

Abstract

Many human (different serotypes) and nonhuman adenovirus vectors are being used for gene delivery. However, the current system for isolating recombinant adenoviral vectors is either time-consuming or expensive, especially for the generation of recombinant non-human adenoviral vectors. We herein report a new and simple cloning approach for the rapid generation of a porcine adenovirus (PAdV-3) vector which shows promise for gene transfer to human cells and evasion of human adenovirus type 5 (HAdV-5) immunity. Based on the final cloning plasmid, pFPAV3-CcdB-Cm, and our modified SLiCE strategy (SLiCE cloning and lethal CcdB screening), the process for generating recombinant PAdV-3 plasmids required only one step in 3 days, with a cloning efficiency as high as 620 ± 49.56 clones/ng and zero background (100% accuracy). The recombinant PAdV-3 plasmids could be successfully rescued in porcine retinal pigment epithelium cells (VR1BL), which constitutively express the HAdV-5 E1 and PAdV-3 E1B 55k genes, and the foreign genes were highly expressed at 24 h after transduction into swine testicle (ST) cells. In conclusion, this strategy for generating recombinant PAdV-3 vectors based on our modified SLiCE cloning system was rapid and cost-efficient, which could be used as universal cloning method for modification the other regions of PAdV-3 genome as well as other adenoviral genomes.

Introduction

Adenovirus-based vectors have been demonstrated to be excellent gene delivery vehicles in mammals [1–4], and certain features of these vectors have made them potential candidates for vaccine development and gene therapy [5]. For example, adenovirus-based vectors can deliver specific genes of interest to a broad spectrum of both actively dividing and post-mitotic quiescent mammalian cells. In addition, the genome of adenovirus vectors has large insert capacity,
and the transgene can be expressed at a high level by strong heterologous promoters. These vectors can also be easily grown to high titers in tissue culture (10^9–10^10 infectious units per ml, IFU/ml). Moreover, the vector genome rarely integrates into the host chromosome and remains primarily episomal; hence, their use is safe, with the low risk of insertional mutagenesis [6]. Human adenovirus serotype 5 (HAdV-5) vectors are well characterized and currently widely used in gene therapy and vaccine development. However, majority of humans contain circulating antibodies against HAdV-5 capsid proteins (fiber, hexon, penton) [7, 8]. In addition, adenovirus often elicits strong innate inflammatory responses within hours after administration, especially in the present of HAdV-5 immunity [9]. Due to the strong activation of innate immune response and the pre-existing immunity (PEI) to HAdV-5, the gene transfer and duration of transgene expression for gene therapy is limited. Meanwhile, the potential toxicity of HAdV-5 to liver and spleen limited the efficacy of vaccine development based on HAdV-5 as well. To circumvent PEI to HAdV-5, one promising alternative being explored is the development of non-human adenovirus vectors [10,11]. Indeed, the absence of cross-neutralization by sera containing HAdV-5-specific antibodies and circumventing the preexisting immunity in humans have helped to initiate the evaluation of porcine adenovirus serotype 3 (PAdV-3) as a vector for the delivery of vaccine antigens in humans [12]. PAdV-3 is also being evaluated as a vaccine delivery vehicle in animals [13–17]. Although PAdV-3 is being developed as a vaccine delivery vehicle, the efficient evaluation of the PAdV-3 vector system requires the rapid generation of PAdV-3 vectors.

The conventional methods for constructing the PAdV-3 vector system are digestion-ligation based on in vitro restriction endonucleases and DNA ligases, in vivo homology recombination in E. coli or a combination of both. However, these methods are still limited by several factors, including the difficulty of selecting restriction endonuclease sites, the low efficiency and difficulty in screening for positive homologous recombination and the requirement of additional time and labor. Thus, the availability of an efficient, robust and universal approach for constructing recombinant porcine adenoviral vector is urgently needed.

SLiCE (Seamless Ligation Cloning Extract) is a novel cloning method that utilizes an easy-to-generate PPY strain cell extract to construct complex recombinant DNA molecules in a single in vitro recombination reaction [18]. As the PPY strain was engineered to constitutively express the λ prophage redβ and gam genes under the control of the EM7 and Tn5 promoters, respectively, and also the redα gene under the control of an arabinose-inducible pBAD promoter (araC-pBAD), the cell extract of PPY strain contains the recombinase of redβγ which could greatly promoted the in vitro homologous recombination with 20–40 bp homology.

Compared with the traditional cloning method, SLiCE cloning has several advantages. (1) SLiCE facilitates seamless cloning without leaving any unwanted sequences at the cloning junctions. (2) SLiCE is a time- and labor-saving strategy that allows the generation of more complex recombinant plasmids using multiple inserts in a single cloning reaction with high efficiency and accuracy. (3) SLiCE is highly cost effective, as the SLiCE extract can be obtained from certain laboratory RecA- bacterial strains, such as DH10B and JM109 [18].

In this study, we report for the first time the successful development of an efficient, robust and universal approach for the construction of recombinant porcine adenoviral vectors in a seamless and precise fashion based on our modified SLiCE cloning method.

**Materials and Methods**

**Cell culture**

Porcine retinal pigment epithelium cells (VR1BL) [19], which were established and stored in our laboratory, were cultured in minimum essential medium (MEM) supplemented with 10%
fetal calf serum (FCS). VR1BL cells constitutively express the HAdV-5 E1 and PAdV-3 E1B 55k genes. Swine testicle (ST) cells obtained from ATCC (CRL-1746) were cultured in MEM supplemented with 5% FCS.

Bacteria, plasmid, virus and viral DNA

*Escherichia coli* strain PPY was a gift from Dr Yongwei Zhang (Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA). *E. coli* DB3.1, which was used for generating a plasmid with the lethal CcdB gene, was purchased from Invitrogen. MAX Efficiency DH10B chemically competent cells were also purchased from Invitrogen. The plasmid pAd-PL/Dust was a gift from Dr Jun Luo (College of Animal Science and Technology, Northwest Agriculture and Forestry University, China) and used as a DNA template for the amplification of the CcdB-Cm expression cassette. The plasmid Ad-Track was purchased from Agilent Technologies, Inc. Viral genomic DNA was extracted from recombinant PAV219-infected monolayers of VR1BL cells according to reported methods [19, 20], and the recombinant PAdV-3 plasmids in this study originated from PAdV-3 strain 6618 (GenBank Accession No. AF083132.1; genome size of 34,094 bp).

Preparation of SLiCE extract

The SLiCE extract was prepared based on the protocol from Dr Zhang [18]. Briefly, *Escherichia coli* strain PPY was grown at 37°C in 2×YT medium until an OD600 > 5.0. The cells were subsequently incubated for 2 h in 2×YT medium containing 0.2% L-arabinose to express the prophage protein λ Redα. The cells were harvested by centrifugation at 5000 g for 20 min at 4°C, washed once with ddH2O and resuspended in CellLytic B Cell Lysis Reagent (Sigma). The resuspended cells were incubated at room temperature for 10 min to allow lysis to occur. The cell lysates were then centrifuged at 20,000 g for 2 min at room temperature to pellet the insoluble material, and the resulting supernatants were carefully removed from the cell debris and mixed with an equal volume of 100% glycerol. The mixture was aliquoted into 40–60 μl portions and stored at -80°C.

Plasmid construction

**Generation of recombinant plasmid pFPAV3-CcdB-Cm.** A flowchart for construction of the porcine adenoviral vector system is described in Fig 1. Briefly, for the generation of a plasmid harboring the E1-deleted PAdV-3 genome, we first constructed shuttle vector pPAV3, which is composed of five fragments. Each fragment is designed to contain 15–20 bp homologies in head to tail format for assembly in a single cloning step to generate shuttle vector pPAV3 using the multiple-way SLiCE cloning protocol. Three fragments were amplified by PCR using PAdV-3 genomic DNA as the template with the indicated primers: fragment I (left ITR to 525 bp of the PAdV-3 genome; primers P1 and p2 in Table 1), fragment III (3,273–3,678 bp of the PAdV-3 genome containing pIX; IX Table 1) and fragment IV (33,848–IV genome containing the right ITR and partial E4 region; primers P7 and P8 in Table 1). Fragment II, containing the CMV-PlacI-BGHpA cassette, was amplified by PCR using primers P3 and P4 (Table 1) and template pCDNA3.1 (+) DNA. Fragment V, containing a 3-kb PacI fragment harboring the vector backbone, was isolated by PacI digestion of the plasmid pAd-track (shuttle vector of Adeasy system). Fragments I, II, III and IV were treated with DpnI prior to purification to remove residual plasmid template DNA. The vector (Fragment V) and these PCR inserts were subjected to gel electrophoresis and purified using the QIAEX II gel extraction kit. The SLiCE reaction mixture contained the following ingredients: 1 μl 10×SLiCE buffer (500 mM pH 7.5 Tris-HCl, 100 mM MgCl₂, 10 mM ATP, 10 mM DTT), 1 μl linear vector (50 ng),
1 μl insert DNA (containing four inserts with a 1:10 molar ratio of vector to insert), 1 μl SLiCE extract and ddH2O in a total volume of 10 μl. The SLiCE reaction mixture was incubated at 37°C for 1 h, and subsequently 1 μl of the SLiCE reaction was transformed into 100 μl MAX Efficiency DH10B chemically competent cells (Invitrogen) following the manufacturer’s instructions. The transformed cells were plated on agar plates containing the appropriate antibiotics.

In addition, a plasmid, pFPAV3, containing an E1-deleted PAdV-3 genome was generated by recombination between PstI-linearized pPAV3 and linear genomic DNA extracted from PAV219 virus-infected VR1BL cells according to the SLiCE cloning method (Fig 1).

To establish a universal and zero background cloning method for foreign gene insertion, we further cloned the positive/negative double selection marker CcdB-Cm into the unique PmeI restriction site of the intermediate genome plasmid pFPAV3 (Fig 1). Briefly, a 1786-bp fragment containing the CcdB-Cm expression cassette was amplified using primers (P9 and P10 in Table 1) and pAd-PL/Dust DNA as the template. As the 1786-bp fragment also contains 20 bp at each end that are homologous to the respective ends generated by Pmel digestion of plasmid pFPAV3, the recombinant pFPAV3-CcdB-Cm plasmid was generated by the SLiCE cloning method using the 1786-bp fragment containing CcdB-Cm and Pmel-digested pFPAV3 (Fig 1).
Incorporation of a foreign gene into pFPAV3-CcdB-Cm based on SLiCE cloning and lethal CcdB screening.

To determine the foreign gene cloning efficiency based on SLiCE cloning and lethal CcdB screening, we constructed recombinant plasmids pFPAV3-EGFP, pFPAV3-Fluc and pFPAV3-LacZ by cloning as the inserts the reporter genes EGFP (plasmid pEGFP-N1, Clontech), firefly luciferase (plasmid pG5-Luciferase, Promega) and LacZ (plasmid pAAV-LacZ, Cell Biolabs) into pFPAV3-CcdB-Cm between the two PmeI sites instead of the CcdB-Cm cassette (Fig 2).

Identification the efficiency of the modified SLiCE method.

The efficiency of the modified SLiCE method is determined by both cloning efficiency and cloning accuracy. The cloning efficiency are given as colonies amount post recombination with per nanogram of vector (vector: insert = 1: 10 molar ratio). The cloning accuracy is given as the percentage of positive clones among 48 randomly selected clones on kanamycin plates. The positive clones were determined by restriction enzyme digestion (Hind III or EcoR I) and sequencing with primers T7 pro and BGHpA rev in Table 1. In this study, we used the sequencing results to identify whether the foreign genes were exactly inserted into recombinant plasmids. Thus the positive sequencing results only represent the correct junctions post foreign genes insertion.

Isolation of recombinant adenoviruses

Monolayers of VR1BL cells grown in a six-well dish were separately transfected with Pac I-linearized pFPAV3-EGFP, pFPAV3-Fluc and pFPAV3-LacZ DNA using Lipofectin Reagent (Invitrogen) according to the manufacturer’s recommendations. Cells showing cytopathic effects were collected, freeze-thawed and propagated for 3–4 passages. The titers of the corresponding rPAV3s were determined using the 50% tissue culture infective dose (TCID₅₀) assay [21].

Table 1. Primer and oligonucleotide list.

| Fragment                     | Sequence (5’-3’)                      |
|------------------------------|---------------------------------------|
| PAV3 genome (1nt-525nt)      | P1 GCTTTAGGGTATAACAGGGTAATTATAAATCATCATCAATAATATACCGCACACTTTTT |
|                              | P2 GTTTAAAAAGCTTTGTGGCTGAGGAAAAACTCTAC |
| CMV cassette                 | P3 GTTTTTCTTCAGCCGACAGCTGTTAATATATACCGCACACTTTTT |
|                              | P4 CATGGAGCGGGTTGCTGAGCCTGGCCGCAGCTCCGCAGCGCGCTTG |
| PAV3 genome (3273nt-5678nt)  | P5 GCTGGGCGGAGCACTGGGACCAACCGGTCGCAGTCTTGTT |
|                              | P6 CATCTTTCCCACTAGGCCTCCCTCTCTTTAAGGCTTGTCCAGAAGCTGAG |
| PAV3 genome (33848nt-34094nt)| P7 CTACGCTCTGGAACAGCACTTAAGGAGGCTGAGGGAAGATG |
|                              | P8 AAATCTAGGATACAGGGTAATTTAAATTACATCATCAATAATATACCGCACACTTTTT |
| CcdB-Cm cassette             | P9 GACCTCATAAGGCACTTGTTAATAACTAGCACGACTGATCGCATGACATAG |
|                              | P10 GAGGCTGATGCGGCTTTAAACTGTCTGCTGAAAACTCAGATG |
| EGFP gene                    | P11 GACCTCATAAGGCACTTGTTAATAACTAGCACGACTGATCGCATGACATAG |
|                              | P12 GAGGCTGATGCGGCTTTAAACTGTCTGCTGAAAACTCAGATG |
| Firefly luciferase gene      | P13 GACCTCATAAGGCACTTGTTAATAACTAGCACGACTGATCGCATGACATAG |
|                              | P14 GAGGCTGATGCGGCTTTAAACTGTCTGCTGAAAACTCAGATG |
| Lac Z gene                   | P15 GACCTCATAAGGCACTTGTTAATAACTAGCACGACTGATCGCATGACATAG |
|                              | P16 GAGGCTGATGCGGCTTTAAACTGTCTGCTGAAAACTCAGATG |
| T7 pro                       | TTAATACGACTATAGGG |
| BGHpA rev                    | TAGAAAGCACAGGGTGG |

doi:10.1371/journal.pone.0127958.t001
Virus growth

The PAdV-3s growth properties were determined by infectious titer, also called the titer of infectious virions post PAV219 or individual recombinant viruses infection (at 0.1 MOI and infection 1×10⁵ VR1BL cells). At the indicated times post infection, the infected VR1BL cells were lysed by five rounds of freeze-thaw, and the titer of infectious virions was calculated by counting the average TCID₅₀ of triple repeat according to Reed—Muench method [21].

Virus transduction

To evaluate the expression of target genes, ST cells (1×10⁵ cells /well of a six-well plate) plated 1 day prior to infection were infected with 1 and 100 MOIs of the indicated recombinant PAdV-3s. At 24 h post-infection, the cells were analyzed. a) EGFP expression in PAV3-EGFP-infected cells was observed using fluorescent microscopy and analyzed by FACS (Beckman Coulter). b) Firefly luciferase signals were detected in pFPAV3-Fluc-infected cells lysates using the Luciferase Report assay system (Promega) in accordance with the manufacturer’s instructions. c) β-Galactosidase expression in PAV3-LacZ-infected cells was determined by X-gal staining, as described previously [22].

Results

Development of a porcine adenoviral vector system

To rapidly generate a recombinant porcine adenovirus, a novel vector system was constructed (Fig 1). The resulting plasmid was named pFPAV3-CcdB-Cm and had the following features. First, a gene expression cassette comprising a CMV promoter and BGHpA was placed in the

---

**Fig 2. Schematic of recombinant porcine adenoviral vector construction and viral packaging.** The recombinant PAdV-3 vector was constructed based on the SLICE strategy by recombination between the PmeI-linearized genome vector pFP AV3-CcdB-Cm and a PCR fragment of a foreign gene containing 20-bp homologies. After a one-hour/one-tube in vitro reaction at 37°C, the SLICE reaction mixture was subsequently transformed into DH10B competent cells and spread on plates containing kanamycin. Randomly selected clones were further confirmed by restriction enzyme analysis and sequencing. The positive recombinant PAdV-3 vectors were linearized by PacI to liberate both inverted terminal repeats (ITRs) and then transfected into VR1BL cells for viral rescue.

---

**doi:**10.1371/journal.pone.0127958.g002

Rapid Generation of Porcine Adenovirus Vectors

PLOS ONE | DOI:10.1371/journal.pone.0127958 May 26, 2015 6/15
E1 region, which is useful for expression of the transgene in vitro and in vivo. Second, the vector contains Pme I restriction enzyme sites between the CMV promoter and BGHpA for foreign gene insertion using the SLiCE cloning method in vitro. Third, the lethal CcdB gene and Cm gene expression cassettes were placed between the two Pme I restriction enzyme sites, allowing recombinants to be selected through lethal CcdB screening.

**Efficiency of foreign gene cloning into pFPAV3-CcdB-Cm**

To identify the cloning efficiency based on the SLiCE strategy, three reporter genes, EGFP, Fluc and LacZ, were individually inserted into the pFPAV3-CcdB-Cm vector to generate recombinant adenoviral vectors pFPAV3-EGFP, pFPAV3-Fluc and pFPAV3-LacZ, respectively (S1 Fig). After screening by lethal CcdB on 50 mg/L kanamycin plates, DNA from randomly selected bacterial colonies was isolated, digested with Hind III or EcoRI and analyzed by agarose gel electrophoresis. As expected (S2–S5 Figs And Fig 3), fragments of 19,690 bp, 11,772 bp, 2,757 bp, 2,226 bp and 170 bp were detected for the Hind III-digested plasmid pFPAV3-CcdB-Cm, and the 2,757-bp fragment in the Hind III restriction enzyme map of pFPAV3-CcdB-Cm was replaced with a 971-bp, 2,649-bp or 4,124-bp fragment in pFPAV3-EGFP, pFPAV3-Fluc and pFPAV3-LacZ, respectively. As the Hind III restriction enzyme maps between plasmid pFPAV3-CcdB-Cm and pFPAV3-Fluc were similar and the EcoRI site in the CcdB/Cm gene of pFPAV3-CcdB-Cm was missing in FLuc insertion of pFPAV3-Fluc, we separately distinguished the recombinant pFPAV3-Fluc from parental plasmid pFPAV3-CcdB-Cm with EcoRI restriction enzyme digestion. As shown in Fig 3, fragments of 17,638 bp, 13,284 bp, 5,315 bp and 870 bp were detected for the EcoRI-digested plasmid pFPAV3-CcdB-Cm as predicted. The 5,135bp—EcoRI fragment in the restriction enzyme map of pFPAV3-CcdB-Cm was diminished in EcoRI-digested plasmid pFPAV3-Fluc. Instead, the 17,638 bp fragment in EcoRI-digested map of pFPAV3-CcdB-Cm was replaced by 22,845 bp (Fig 3). Moreover, the restriction enzyme analysis confirmed that all the randomly selected clones were positive for insertion of the reporter gene. The clone accuracy was further proven by DNA sequencing with the sequencing primer T7 pro and BGHpA rev (Table 1) of the plasmid pCDNA3.1(+) (data not shown). The efficiencies for EGFP (0.7 kb), Luc (1.7 kb) and LacZ (3.1 kb) cloning based on our modified SLiCE strategy (SLiCE cloning and lethal CcdB screening) was as high as 620±49.56, 490±26.88 and 370±50.99 clones/ng of plasmid, respectively. And the cloning accuracy were almost 100% positive after Hind III or EcoRI restriction enzyme analysis and the junctions sequencing (data not shown)(Table 2).

**Analysis of recombinant PAV3-EGFP, PAV3-Fluc and PAV3-LacZ**

The plasmids pFPAV3-EGFP, pFPAV3-Fluc and pFPAV3-LacZ were individually transfected into VR1BL cells for the isolation of recombinant porcine adenoviruses. As shown Fig 4a, typical cytopathic effects including cell rounding, morphological irregularity, swelling/shrinking and detachment were observed at 9 days post-transfection. The infected cells were collected and freeze-thawed three times, and recombinant viruses PAV3-EGFP, PAV3-Fluc and PAV3-LacZ were proliferated in VR1BL cells. To determine growth properties or infectious titer of PAV219 or individual recombinant viruses, virus-infected VR1BL cells (at 0.1 MOI and infection 1×10⁵ cells) were collected at different times post-infection and analyzed by a TCID₅₀ assay. As observed in Fig 4b, the recombinant PAdV-3s grew as efficiently as PAV219, and reporter gene expression was successfully detected in the virus- transduced ST cells (Fig 5).
Table 2. Comparison of the cloning efficiencies for different insertion lengths.

| Vector                  | Insert       | Cloning efficiency | Cloning accuracy (%) |
|-------------------------|--------------|--------------------|----------------------|
| Linear pFPAV3-CcdB-Cm   | EGFP (0.7 kb)| 620±49.56          | 100                  |
|                         | Luc (1.7 kb)| 490±26.88          | 100                  |
|                         | LacZ (3.1 kb)| 370±50.99         | 100                  |

a. The linear pFPAV3-CcdB-Cm vector was generated by Pme I digestion.
b. The EGFP, Luc and LacZ inserts flanked with 20-bp homologies were generated by PCR.
c. The cloning efficiencies of different insertion length are represented by colonies for per nanogram vector.
d. The cloning accuracy is represented by the percentage of positive colonies among the total identified clones after restriction enzyme analysis and sequencing.
e. Luc: Firefly luciferase gene.

doi:10.1371/journal.pone.0127958.t002
Discussion

Human adenovirus type 5 (HAdV-5)-based vectors have emerged during the last two decades as a promising gene delivery platform for a variety of therapeutic and vaccine purposes. However, HAdV-5 vector might induce associated acute toxicity as well as diminish the efficacy of therapeutic targeting following systemic administration in patient, due to the interactions between HAdV-5 capsid proteins and its receptors in the target cells including: (1) activation of macrophages, natural killer (NK) cells and classical complement pathway; (2) high transduction
of immune cells in the liver and spleen; (3) induce inflammatory cytokines secretion [23–25]. In addition, the pre-existing immune of HAdV-5 further increases the histologic hepatic damage and limits the efficacy of gene therapy and vaccine development based on HAdV-5 vector [26–28]. To overcome these drawbacks, recombinant adenoviral vectors based on different genetic modifications of HAdV-5 capsids, different Helper-Dependent Adenoviral (HD-Ad) Vectors, less prevalent HAdV serotypes vectors (such as HAdV-11, HAdV-26 and HAdV-35) and non-human adenoviral vectors from different species (such as canine, bovine, porcine, murine, fowl, ovine and simian) were being evaluated [19, 29–36]. As one alternative non-human adenovirus, porcine adenovirus serotype 3 (PAdV-3) has many qualities which make it an ideal choice for use as a delivery vector, such as low grade pathogen, species specific infection following administration, knowledge of full length genome sequence, wide cell transduction in different species of including humans and other animals, circumvention of HAdV-5 vector-specific neutralizing antibody response [37–39]. Nonetheless, the isolation of recombinant PAdV-3 vectors by available methods [19, 34–36] is either time-consuming or expensive.

To date, many conventional systems for recombinant adenoviral vector construction have been established in accordance with in vitro cloning methods by digestion-ligation, Gateway or In-Fusion technology, and in vivo cloning methods by RecA, λ prophage Red, Cre/LoxP or Flp/Frt recombination in E. Coli [40–46]. Based on aforementioned cloning technology, four commercial systems, Adeno-X Expression System I (Clontech), Adeasy (Stratagene), ViraPower Adenoviral Expression System I (Invitrogen) and Adeno-X Expression System 3 (Clontech), have been widely applied all over the world. For rare restriction enzymes, ligation of Adeno-X Expression System I and RecA recombination in the Adeasy system, the gene cloning efficiency is typically variable (from 20% to 90%) due to the contamination of non-cutting adenoviral plasmid, non-cutting shuttle plasmid, and/or difficulty in large-fragment ligation. Although the gene cloning efficiency and accuracy for ViraPower Adenoviral Expression System and Adeno-X Adenoviral System 3 is nearly 100%, these two systems are highly dependent on the use of expensive restriction enzyme-mediated Gateway and In-Fusion cloning (S6 Fig and S1 Table).

The in vivo λ prophage Red system for recombinant adenoviral vector construction reported by Samuel Campos and Michael Barryis depends on the recombination in strain BW25113 harbors pKD46, a temperature-sensitive plasmid encoding the Red genes under control of the pBAD L-arabinose inducible promoter, and FLP-mediated removal of the FRT-flanked ZeoR cassettes in DH5α strain harboring pCP20, a chloramphenicol-resistant temperature sensitive plasmid for the expression of FLP recombinase [44]. Different from the conventional in vivo cloning based on λ prophage Red recombination, we developed a novel, efficient and zero-background cloning method for the generation of recombinant PAdV-3 vectors based on SLiCE cloning and lethal CcdB screening in this study. The SLiCE cloning is one type of in vitro cloning methods based on λ prophage Red recombination with 20–40 bp homology. As illustrated in Fig 2, the novel strategy developed involves three major steps. First, the gene of interest containing 20–40 bp homologies is generated by PCR. Second, the gene of interest flanked with 20–40 bp homologies is cloned into the backbone vector based on the SLiCE cloning method and lethal CcdB gene screening. Multiple restriction digestion analysis is performed for further identification. Third, the recombinant porcine adenoviral plasmid is cleaved with PacI to expose its inverted terminal repeats and then transfected into a packaging cell line (VR1BL cells). The SLiCE cloning method, the positive selection by the lethal CcdB gene and the ability to bypass further identification steps make the construction of porcine adenoviral vectors using this approach simple and efficient.

Comparing with the reported methods for recombinant adenoviral vector construction, our modified SLiCE system has several advantages. First, a shuttle plasmid and restriction
enzyme-mediated ligation is not needed. The gene of interest with flanking 20–40 bp homologies is generated by a single PCR amplification and is directly cloned into a linearized adenoviral plasmid in a one-hour/one-tube \textit{in vitro} reaction followed by standard transformation of host bacteria. Second, the cloning efficiency can reach as high as 620±49.56 clones/ng of plasmid, and the cloning accuracy based on the SLiCE cloning and lethal CcdB screening strategy was almost 100% by restriction enzyme analysis and the insertion junctions sequencing (Not sure whether all the recombinant clones on plate were 100% positive). Third, by avoiding the steps to prior the treatment of end sequences by enzymes, SLiCE cloning is very cost efficient. Finally, the virus growth and transduction efficiency of the recombinant PAdV-3 vectors isolated using the SLiCE system appeared to be comparable to a recombinant PAdV-3 isolated using a conventional system. The detailed comparison of our modified SLiCE system with current commercial systems is provided in S6 Fig and S1 Table.

To our knowledge, the method described herein is the first successful example of the application of the SLiCE cloning method to the construction of recombinant adenoviral vectors. The CcdB-Cm marker in pFPAV3-CcdB-Cm cloning plasmid was used for double screening of the positive clones for the recombinant adenoviral plasmid, by which non-recombinant or partially recombinant clones are eliminated [47]. The Cm marker could be further used to detect the contamination of non-recombinant pFPAV3-CcdB-Cm vectors, though the Cm screening step in our work was replaced by the step of restriction enzyme analysis.

In summary, our porcine adenovirus system based on the SLiCE cloning method and lethal CcdB gene screening is an easy, efficient and inexpensive cloning method that allows the generation of recombinant porcine adenoviral vectors in a seamless and precise fashion. Although we evaluated and established this versatile cloning method for modification the E1 region of PAdV-3 vectors in this study, this method can also be utilized to modify the other regions such as fiber, hexon or pIX within the PAdV-3 genome, as well as the adenoviral vectors based on human and other non-human adenovirus.

Supporting Information

S1 Fig. Schematic of recombinant porcine adenoviral vectors containing different transgenes. The genes for EGFP (0.7kb), firefly luciferase (1.7kb) and lac Z (3.1kb) flanked with 20-bp homologies were cloned into the pFPAV3-CcdB-Cm vector using the SLiCE strategy (TIF)

S2 Fig. The map of the parent plasmid pFPAV3-CcdB-Cm. The Hind III and EcoRI sites were shown in the maps of the parental plasmid pFPAV3-CcdB-Cm. The Hind III sites and Hind III cleavage fragment for differentiation three recombinant constructions from the parental plasmid pFPAV3-CcdB-Cm were labeled in red. In addition, the unique EcoRI site within the CcdB-Cm gene of the parental plasmid pFPAV3-CcdB-Cm was also labeled in red, which was only used for differentiation the plasmid pFPAV3-Fluc from parent plasmid pFPAV3-CcdB-Cm as this EcoRI site was missing in plasmid pFPAV3-Fluc. (TIF)

S3 Fig. The map of the result plasmid pFPAV3-EGFP. The Hind III and EcoRI sites were shown in the maps of the plasmid pFPAV3-EGFP. The Hind III sites and Hind III cleavage fragment containing the EGFP gene were labeled in red. (TIF)

S4 Fig. The map of the result plasmid pFPAV3-Fluc. The Hind III and EcoRI sites were shown in the maps of the plasmid pFPAV3-EGFP. The Hind III sites and Hind III cleavage...
fragment containing the Fluc gene were labeled in red.

(TIF)

**S5 Fig. The map of the result plasmid pFPAV3-LacZ.** The Hind III and EcoRI sites were shown in the maps of the plasmid pFPAV3-LacZ. The Hind III sites and Hind III cleavage fragment containing the LacZ gene were labeled in red.

(TIF)

**S6 Fig. Schematic representation of the construction of recombinant adenoviral vectors.** (a) Foreign gene cloning based on Adeno-X Expression System I. The foreign gene was cloned into the MCS between I-CeuI and PI-SceI sites of the shuttle plasmid pShuttle. Then, the shuttle vector and the genome vector were both double digested with I-CeuI and PI-SceI for in vitro ligation. To avoid the contamination of un-cut plasmid, the ligation products were pre-digested by Swal before transformation. (b) Foreign gene cloning based on the Adeasy system. The foreign gene was cloned into the MCS of the shuttle plasmid pAd-Shuttle. Then, the Pmel-linearized pAd-Shuttle-GOI plasmid was transformed into BJ5183 competent cells pre-transformed with genome plasmid pAdeasy-1. After recombination, the DNA of kanamycin-resistant clones was isolated from BJ5183 cells and re-transformed into other high-copy strains to produce a large amount of viral vector. (c) Foreign gene cloning based on the Gateway system. The foreign gene was cloned into the MCS of the shuttle vector p-Entry. Then, the GOI was transferred from the shuttle plasmid p-Entry-GOI into the adenoviral vector pAd-CMV-Dust by LR clonase-mediated recombination. (d) Foreign gene cloning based on Adeno-X Expression System 3. The foreign gene flanking with 20-bp homologies was cloned into the adenoviral vector by In-Fusion enzyme-mediated recombination. (e) Foreign gene cloning based on our modified SLiCE system. The foreign gene flanking with 20-bp homologies was cloned into the adenoviral vector using the crude cell extracts of *Escherichia coli* strain PPY after induction with L-arabinose.

(TIF)

**S1 Table. Comparison of four methods for recombinant adenoviral vector construction.**

(DOC)

**Acknowledgments**

We thank Dr Yongwei Zhang (Department of Cell Biology, Albert Einstein College of Medicine) for *Escherichia coli* strain PPY. This work was supported by the Research Starting Foundation, Northwest A & F University (Grant No. Z111021006), National Natural Science Foundation of China (Grant No.31101803/C1803) and Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences (Grant No. SKLVBF201405).

**Author Contributions**

Conceived and designed the experiments: SKT ZY. Performed the experiments: PZ ED. Analyzed the data: JM. Contributed reagents/materials/analysis tools: WW LZ. Wrote the paper: PZ.

**References**

1. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869), 331–335. doi:10.1038/415331a PMID: 11797011

2. Dobbelstein M (2004) Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol. 273, 291–334. doi: 10.1007/978-3-662-05599-19 PMID: 14674605
16. Hammond JM, Jansen ES, Morrissy CJ, Williamson MM, Hodgson AL, Johnson MA (2001) Oral and
Zhang Y, Werling U, Edelmann W (2012) SLiCE: a novel bacterial cell extract-based DNA cloning
18. Hammond JM, Jansen ES, Morrissy CJ, Hodgson AL, Johnson MA (2003) Protection of pigs against
17. 2003) A recombinant E1-deleted porcine adenovirus-3 as an ex-
19. Zakhartchouk A, Zhou Y, Tikoo SK (2003) A recombinant E1-deleted porcine adenovirus-3 as an ex-
20. Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL (1998) Factors that influence stability
22. Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine.
10. Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 24(7), 849–862. doi:10.1016/j.vaccine.2005.08.101 PMID: 16297508
11. Moffatt S, Hays J, HogenEsch H, Mittal SK (2000) Circumvention of vector-specific neutralizing anti-
body response by alternating use of human and non-human adenovirus: implications in gene ther-
apy. Virology. 272(1), 159–167. doi:10.1006/viro.2000.0350 PMID: 10873758
12. Patel A, Tikoo S, Kobinger G (2010) A porcine adenovirus with low human seroprevalence is a promis-
13. Hammond JM, Mccoy RJ, Jansen ES, Morrissy CJ, Hodgson AL, Johnson MA (2000) Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine. 18(11–12), 1040–1050. doi:10.1016/S0264-410X(99)00347-3
14. Hammond JM, Jansen ES, Morrissy CJ, van_der_Heide B, Goff WV, Williamson MM, et al (2001) Vac-
cination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies
15. Hammond JM, Jansen ES, Morrissy CJ, Goff WV, Meehan GC, Williamson MM, et al (2001) A prime-
boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs
16. Hammond JM, Jansen ES, Morrissy CJ, Williamson MM, Hodgson AL, Johnson MA (2001) Oral and
sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Archives of Virology. 146(9), 1787–1793. doi:10.1007/s007050170064 PMID: 11699963
17. Hammond JM, Jansen ES, Morrissy CJ, Hodgson AL, Johnson MA (2003) Protection of pigs against 'in
contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombi-
nant porcine adenovirus. Virus Research. 97(2), 151–157. doi:10.1016/j.virusres.2003.08.003 PMID: 14602208
18. Zhang Y, Werling U, Edelmann W (2012) SLICE: a novel bacterial cell extract-based DNA cloning
method. Nucleic Acids Res. 40(8), e55. doi:10.1093/nar/gkr1288 PMID: 22241772
19. Zakharchtchouk A, Zhou Y, Tikoo SK (2003) A recombinant E1-deleted porcine adenovirus-3 as an ex-
pression vector. Virology. 313(2), 377–386. doi:10.1006/viro.2002-6822(03)00286-1 PMID: 12954206
20. Hirt B (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. Journal of Molecular Biology. 26(2), 365–369. doi:10.1016/0022-2836(67)90307-5 PMID: 4291934
21. Li X, Babiu LA, Tikoo SK (2004) Analysis of early region 4 of porcine adenovirus type 3. Virus Res. 104(2), 181–190. PMID: 15246655
22. Croyke MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL (1998) Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm Dev Technol. 3(3), 373–383. doi:10.3109/10837459809009865 PMID: 9742558
23. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. May; 3(5 Pt 1):708–22. PMID: 11356076
24. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al (2003) Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. Sep-Oct; 80(1-2):148–58.

25. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, et al (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol. Nov; 71(11):8796–807. PMID: 9343240

26. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC, et al (2002) Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol. 76:5711–5719. PMID: 11991999

27. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM (2005) Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice. Gene Ther. 12:427–436. PMID: 15647774

28. Stone D, Ni S, Li ZY, Gaggar A, DiPaolo N, et al (2005) Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol. 79(8), 5090–5104. doi: 10.1128/JVI.79.8.5090-5104.2005 PMID: 15795294

29. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J Stanley D, Honko A, et al (2011) Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Non Human Primates against Ebolavirus Challenge. J Virol. 85(9), 4222–4233. doi: 10.1128/JVI.02407-10 PMID: 21325402

30. Reddy PS, Ganesh S, Limbach MP, Brann T, Pinkstaff A, et al (2003) Development of adenovirus serotype 35 as a gene transfer vector. Virology. 311(2), 384–393. doi: 10.1016/S0042-6822(03)00161-2 PMID: 12842627

31. Reddy PS, Idamakanti N, Limbach MP, Mehta S, Gaggar A, DiPaolo N, et al (2009) Development of porcine adenovirus type 3 as an expression vector. J Gen Virol. 80 (Pt 3), 563–570. PMID: 19091994

32. Reddy PS, Idamakanti N, Babyu LA, Babiuk LA (1999) Development of porcine adenovirus-3 as an expression vector. J Gen Virol. 80 (Pt 11), 2909–2916. PMID: 10580052

33. Reddy PS, Idamakanti N, Chen Y, Whale T, Babiuk LA, Mehtali M, et al (1999) Replication-defective bovine adenovirus type 3 as an expression vector. J Virol. 73(11), 9137–9144. PMID: 10516020

34. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK (2009) Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology. 386(1), 44–54. doi: 10.1016/j.virol.2009.01.008 PMID: 19211122

35. Sharma A, Bangari DS, Tandon M, Hogenesch H, Mittal SK (2010) Evaluation of innate immune and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res. 153(1), 134–142. doi: 10.1016/j.virusres.2010.07.021 PMID: 20659505

36. Sharma A, Tandon M, Ahi YS, Bangari DS, Vemulapalli R, Mittal SK (2010) Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther. 17(5), 634–642. doi: 10.1038/gt.2010.1 PMID: 20164856

37. Bett AJ, Haddara W, Prevec L, Graham FL (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. Sep 13; 91(19):8802–6. PMID: 8090727

38. Chartier C, Degryse E, Gantzner M, Dieterle A, Pavirani A, Mehtali M (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. Jul. 70 (7):4805–10. PMID: 8676512

39. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95(5), 2509–2514. PMID: 9482916

40. Campos SK, Barry MA (2004) Rapid construction of capsid modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther. Nov; 15(11):1125–30. PMID: 15610612
45. Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U, Graham FL (1999) A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther. Nov 1; 10(16):2667–72. PMID: 10566894

46. Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL (2001) Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther. May; 3(5 Pt 1):809–15. PMID: 11356086

47. Bernard P (1996) Positive selection of recombinant DNA by CcdB. BioTechniques. 21(2), 320–323. PMID: 8862819